Telix Pharmaceuticals Announces $1.65 Billion Strategic Merger with Germany's ITM

Key Facts

In a move reflecting the accelerating pace of consolidation within the advanced healthcare sector, Telix Pharmaceuticals has announced a strategic agreement to lead a merger with Germany's ITM Isotope Technologies Munich SE. This transaction aims to combine Telix's pharmaceutical development capabilities with ITM's global leadership in radioisotope production, creating a major entity in the radiopharmaceutical space. According to reports, Telix will acquire 100% of ITM shares for an upfront consideration of $1.65 billion.

The deal significantly strengthens Telix's market position, with Telix shareholders expected to own approximately 76.3% of the combined entity, while ITM shareholders will hold 23.7% of the shares on issue. ITM is a critical supplier of Lutetium-177 and delivered annual revenue of $273 million in 2025. Per market data, TLX stock closed at $12.59 on September 18, 2026, having reached a day high of $12.80 during that session.

Investors are now monitoring TLX price levels following its close at $12.59 (close September 18, 2026) as the market reacts to the merger news. While the upcoming economic calendar shows no immediate sector-specific catalysts, the focus remains on the required shareholder approvals to finalize the transaction. This merger represents a strategic shift to secure the supply chain for Telix's late-stage therapeutic pipeline, including treatments for prostate and kidney cancers.